Organicell Regenerative Medicine Inc. (BPSR.OB) has received FDA clearance to initiate a phase I/II multi-center clinical trial of Organicell Flow in patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection.
from RTT - Biotech https://ift.tt/2WAdjL4
via IFTTT
No comments:
Post a Comment